Vir is holding off on advancing the combination therapy to Phase III trials until it secures a development partner.

Vir Biotechnology, Inc. operates as a clinical-stage immunology company that focuses on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases.